DHEA-S Test: The Anti-Aging Hormone Marker

Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant circulating steroid hormone in the human body and serves as the primary precursor to both androgens and estrogens in peripheral tissues. Produced almost exclusively by the adrenal cortex, DHEA-S declines more dramatically with age than any other hormonal marker, making it a central biomarker in longevity medicine, adrenal health assessment, and hormonal aging research.

Table of Contents

1. Overview
2. When Ordered
3. Reference Ranges
4. Age-Related Decline
5. Adrenal Function Assessment
6. PCOS and Elevated DHEA-S
7. Relationship to Cortisol
8. Supplementation Considerations
9. References

Overview

DHEA (dehydroepiandrosterone) is a 19-carbon steroid synthesized in the zona reticularis of the adrenal cortex from cholesterol via the steroidogenic pathway. The sulfated form, DHEA-S, is produced by the addition of a sulfate group to DHEA, primarily in the adrenal glands, with minor contributions from the liver and small intestine. The sulfation dramatically increases water solubility and extends the hormone's half-life from 1–3 hours (for DHEA) to 7–10 hours (for DHEA-S), making DHEA-S the preferred clinical measurement due to its stability and lack of diurnal variation.

DHEA-S serves as a circulating hormonal reservoir. In peripheral tissues throughout the body — including fat, skin, bone, brain, liver, and reproductive organs — DHEA-S is desulfated back to DHEA and then converted locally into androgens (testosterone, dihydrotestosterone) and estrogens (estradiol, estrone) via tissue-specific enzymes. This intracrine system allows sex hormone synthesis in organs that lack gonads, and is particularly important in postmenopausal women and older men, in whom adrenal DHEA-S becomes the dominant source of sex steroids in peripheral tissues.

Beyond its role as a sex steroid precursor, DHEA-S has documented direct biological effects including immune modulation, neuroprotection, anti-glucocorticoid activity, and cardiovascular protection — positioning it as one of the most biologically consequential hormones in human aging physiology.

Back to Table of Contents

When Ordered

DHEA-S is ordered across a broad range of clinical and preventive medicine contexts:

• Evaluation of androgen excess in women, particularly to differentiate adrenal from ovarian androgen sources — adrenal androgen excess predominantly elevates DHEA-S, while ovarian androgen excess predominantly elevates testosterone
• Workup of suspected polycystic ovary syndrome (PCOS) and determination of the adrenal contribution to hyperandrogenemia
• Assessment of adrenal function in suspected adrenal insufficiency, primary or secondary
• Evaluation of adrenal tumors — markedly elevated DHEA-S warrants imaging to exclude adrenal carcinoma or adenoma
• Investigation of premature adrenarche (early pubic hair development) in children, where elevated DHEA-S confirms early adrenal activation
• Workup of virilization or rapid-onset androgen excess in women, where DHEA-S above 700–800 µg/dL raises concern for adrenal malignancy
• Longevity and hormonal aging assessment in integrative, anti-aging, and functional medicine evaluations
• Monitoring DHEA supplementation therapy in clinical settings
• Assessment of adrenal reserve and stress hormone axis function in patients with chronic fatigue, autoimmune disease, or recurrent infections

Because DHEA-S has minimal diurnal variation (unlike DHEA and cortisol), it can be measured at any time of day and does not require fasting. A single measurement is generally sufficient for clinical assessment.

Back to Table of Contents

Reference Ranges

DHEA-S — Male (µg/dL)

DHEA-S — Female (µg/dL)

Reference ranges are highly age-dependent. The wide normal ranges above span young adulthood through old age. For a 25-year-old male at peak, levels of 400–560 µg/dL are typical, while an 80-year-old male with levels of 80–100 µg/dL is at the lower normal boundary for his age cohort. Markedly elevated levels above 700–800 µg/dL in either sex warrant evaluation to exclude androgen-secreting adrenal tumors. Levels below 40 µg/dL in younger adults are consistent with adrenal insufficiency or hypothalamic-pituitary dysfunction and warrant further hormonal evaluation including ACTH stimulation testing.

Back to Table of Contents

Age-Related Decline

The age-related decline of DHEA-S is one of the most striking hormonal changes in human aging and stands in sharp contrast to cortisol, which declines minimally or remains stable with age. This selective decline produces a progressive shift in the adrenal cortisol:DHEA ratio that is believed to contribute significantly to age-associated immune dysfunction, metabolic deterioration, and degenerative disease susceptibility.

Key features of the DHEA-S aging trajectory:

• Peak levels: DHEA-S reaches maximum concentrations between ages 20–30 years, with men typically peaking at 400–600 µg/dL and women at 300–430 µg/dL.
• Rate of decline: Beginning in the mid-twenties, DHEA-S falls at approximately 2% per year on average. By age 70–80, levels are typically only 10–20% of peak values.
• Sex differences: Men have consistently higher DHEA-S than women throughout adulthood, but both sexes experience proportionally similar rates of decline. Women experience a modest additional DHEA-S reduction at menopause due to ovarian senescence, though the adrenal gland remains the primary DHEA-S source.
• Individual variation: The rate and extent of DHEA-S decline varies considerably between individuals and appears to be influenced by genetic factors, chronic stress, sleep quality, body composition, and chronic disease burden.

Epidemiological studies consistently demonstrate that higher DHEA-S levels in older adults are associated with reduced all-cause mortality, lower rates of cardiovascular disease, better cognitive function, greater physical function and muscle strength, improved immune competence, and lower prevalence of metabolic syndrome. Whether DHEA-S is causally protective or merely a marker of preserved vitality remains an active area of investigation.

Back to Table of Contents

Adrenal Function Assessment

The adrenal cortex produces hormones in three distinct zones: the zona glomerulosa (aldosterone), zona fasciculata (cortisol), and zona reticularis (DHEA/DHEA-S). DHEA-S measurement provides a selective window into zona reticularis function and overall adrenocortical health.

Key clinical applications in adrenal assessment:

• Primary adrenal insufficiency (Addison's disease): Destruction of the adrenal cortex reduces production of cortisol, aldosterone, and DHEA-S. While cortisol and ACTH are the primary diagnostic markers, DHEA-S is invariably low in established primary adrenal insufficiency and can provide supporting evidence. Standard of care for Addison's disease now includes DHEA replacement in women (discussed below), as adrenal androgens are entirely lost.
• Secondary adrenal insufficiency: Pituitary ACTH deficiency impairs cortisol production but also reduces DHEA-S, as both depend on ACTH stimulation. DHEA-S is suppressed in hypopituitarism and after prolonged glucocorticoid therapy (which suppresses ACTH).
• Adrenal carcinoma: DHEA-S above 700–800 µg/dL, particularly in adults, raises suspicion for adrenocortical carcinoma, which often produces large quantities of adrenal androgens. These tumors are typically accompanied by rapid virilization and should prompt CT imaging of the adrenal glands.
• Functional adrenal assessment: In integrative medicine, chronically low DHEA-S in the context of high cortisol, fatigue, and impaired stress tolerance is interpreted as a sign of adrenal dysregulation — sometimes informally termed "adrenal fatigue." This concept lacks formal diagnostic validation but reflects the clinically observed pattern of disrupted cortisol:DHEA-S balance in chronically stressed individuals.

Back to Table of Contents

PCOS and Elevated DHEA-S

Polycystic ovary syndrome (PCOS) is heterogeneous — some women have predominantly ovarian androgen excess (elevated testosterone), others have predominantly adrenal androgen excess (elevated DHEA-S), and many have both. Approximately 20–30% of women with PCOS have elevated DHEA-S, indicating a significant adrenal component to their hyperandrogenism.

The DHEA-S level is particularly useful in PCOS evaluation for several reasons:

• Source differentiation: DHEA-S is produced almost exclusively by the adrenal glands, while testosterone in women originates from both ovaries and adrenals. An elevated DHEA-S with normal-range testosterone points toward adrenal hyperandrogenism; an elevated testosterone with normal DHEA-S implicates the ovaries.
• Treatment implications: Women with predominantly adrenal PCOS may respond differently to treatment. Low-dose corticosteroid therapy (e.g., dexamethasone 0.25–0.5 mg at bedtime) suppresses ACTH-driven adrenal androgen production and can be helpful in this subtype, particularly for ovulation induction when clomiphene alone is insufficient.
• Excluding adrenal tumors: In women presenting with androgen excess symptoms, DHEA-S above 700 µg/dL effectively excludes PCOS as the cause and requires imaging to rule out adrenal neoplasm.
• Insulin resistance connection: Insulin stimulates adrenal androgen production (in addition to its ovarian LH-potentiating effects), meaning that women with PCOS and insulin resistance may have DHEA-S elevation partly driven by hyperinsulinemia. Insulin sensitizers such as metformin or inositol can reduce DHEA-S as a secondary effect.

Back to Table of Contents

Relationship to Cortisol

DHEA and cortisol are both produced by the adrenal cortex in response to ACTH, yet they exert largely opposing physiological effects. Understanding their balance — often expressed as the cortisol:DHEA ratio — provides insight into adrenal health and stress physiology that neither marker conveys in isolation.

Key aspects of the cortisol-DHEA-S relationship:

• Opposing actions: Cortisol is catabolic, immunosuppressive, pro-inflammatory (acutely), and promotes gluconeogenesis. DHEA counteracts these effects — it is anabolic, immune-stimulating, anti-glucocorticoid at the receptor level, and neuroprotective. In physiological stress responses, both hormones rise in concert. But chronic stress chronically elevates cortisol while DHEA-S progressively declines, shifting the balance toward cortisol dominance.
• Cortisol:DHEA ratio as aging biomarker: The cortisol:DHEA ratio rises with aging and chronic stress exposure. Studies in elderly populations and individuals with chronic diseases show higher cortisol:DHEA ratios associated with greater cognitive impairment, immune senescence, bone loss, cardiovascular risk, and all-cause mortality. It is considered a more sensitive indicator of biological aging than chronological age alone.
• Stress, HPA axis, and DHEA-S suppression: Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to persistently elevated cortisol. Over time, this is associated with a relative decline in DHEA-S. Whether this reflects direct suppression, preferential ACTH driving of cortisol over DHEA pathways, or progressive zona reticularis atrophy is still being studied.
• Clinical interpretation: A useful clinical heuristic is to measure both morning cortisol (or a 4-point salivary cortisol profile) and DHEA-S together. A high cortisol with low DHEA-S suggests chronic stress burden. Normal cortisol with low DHEA-S may indicate age-related decline. Low cortisol with low DHEA-S suggests adrenal insufficiency requiring further evaluation.

Back to Table of Contents

Supplementation Considerations

DHEA is available as an over-the-counter dietary supplement in the United States (though it requires a prescription in many other countries) and has been studied in numerous clinical contexts. Supplementation should be individualized and ideally supervised by a clinician with expertise in hormonal health.

• Evidence base for supplementation: The strongest evidence for DHEA supplementation exists in women with primary adrenal insufficiency (Addison's disease), in whom it has been shown to improve mood, well-being, libido, and body composition in RCTs. The European Society of Endocrinology recommends considering a 6-month trial of DHEA supplementation in women with adrenal insufficiency. Evidence in healthy aging adults is more mixed, though benefits in bone density, sexual function, and quality of life have been demonstrated in some studies, particularly in those with the lowest baseline DHEA-S levels.
• Typical dosing: Replacement doses of 25–50 mg/day are most commonly used. Lower starting doses (5–25 mg) may be appropriate for women due to higher androgen sensitivity and the risk of virilizing side effects. Dosing should be guided by follow-up DHEA-S and testosterone measurements.
• Androgen conversion concerns: DHEA can be converted peripherally to testosterone and estrogens. In women, this can cause androgenic side effects including acne, oily skin, facial hair growth, and elevated testosterone. In men, a portion may aromatize to estradiol. Monitoring downstream hormones after initiating supplementation is essential.
• Hormone-sensitive conditions: DHEA supplementation is generally contraindicated in individuals with hormone-sensitive cancers (prostate cancer, breast cancer, ovarian cancer), as conversion to sex steroids may stimulate tumor growth.
• 7-keto DHEA: A metabolite of DHEA that does not convert to sex steroids, 7-keto DHEA is sometimes used as an alternative in individuals concerned about androgenic or estrogenic effects. It has demonstrated benefits for thermogenesis and body composition in some studies but has a different and less characterized mechanism than DHEA itself.
• Lifestyle support of DHEA-S: Several lifestyle factors support healthier DHEA-S levels without pharmacological supplementation. These include consistent aerobic exercise (particularly in older adults), adequate sleep (deep slow-wave sleep supports adrenal recovery and DHEA output), stress management to reduce cortisol burden, caloric adequacy (severe dietary restriction suppresses DHEA-S), and maintaining healthy body weight.

Back to Table of Contents

References

1. Orentreich N, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology and Metabolism. 1984;59(3):551–555.
2. Labrie F, et al. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Frontiers in Neuroendocrinology. 2001;22(3):185–212.
3. Arlt W, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine. 1999;341(14):1013–1020.
4. Baulieu EE, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences USA. 2000;97(8):4279–4284.
5. Morales AJ, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. Journal of Clinical Endocrinology and Metabolism. 1994;78(6):1360–1367.
6. Straub RH, et al. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. American Journal of Gastroenterology. 1998;93(11):2197–2202.
7. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. European Journal of Neuroscience. 2002;16(3):445–453.
8. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men. JAMA. 2004;292(18):2243–2248.
9. Genazzani AR, et al. Adrenal androgen secretion and aging in women. Climacteric. 2011;14(4):470–477.
10. Laughlin GA, Barrett-Connor E. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels. Journal of Clinical Endocrinology and Metabolism. 2000;85(3):1168–1176.
11. Majewska MD, et al. Neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Research. 1990;526(1):143–146.
12. Hammer F, Stewart PM. Cortisol metabolism in hypertension. Best Practice and Research: Clinical Endocrinology and Metabolism. 2006;20(3):337–353.